No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

byAstrid BradshawandAlisha Yi

September 4, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in the Lancet.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Pembrolizumab improves survival in locally advanced head and neck cancer

AI scans detect pancreatic cancer years before clinical diagnosis

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial

RelatedReports

Elective neck dissection may be unnecessary for adenoid cystic carcinoma

Oncology

Pembrolizumab improves survival in locally advanced head and neck cancer

August 26, 2025

Half of parents aware of CT radiation cancer risk

AI Roundup

AI scans detect pancreatic cancer years before clinical diagnosis

July 30, 2025

StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025

Lessons from real-world implementation of lung cancer screening

Oncology

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

July 7, 2025

Intravenous amino acids decrease acute kidney injury following cardiac surgery

Oseltamivir and peramivir may reduce length-of-hospital-stay in patients with severe influenza

Epileptogenic foci may be lateralized using functional brain glutamate imaging

Liberal transfusion strategy does not improve post-traumatic brain injury neurologic outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result